[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2010年修订版)[J].中华肝脏病杂志,2010,18(3):163-166.
[2] 孟艳秋,刘文虎,刘凤鑫,等.抗2型糖尿病药物研究进展[J].现代药物与临床,2013,28(3):461-464.
[3] 赵大鹏,隋艳波,栾仲秋,等.洋参御糖方对糖尿病大鼠糖脂代谢的干预作用[J].中医药信息,2013,30(2):44-45.
[4] 吴景程,李晓华,彭永德,等.2型糖尿病患者非酒精性脂肪肝与微血管病变关系的研究[J].中国实用内科杂志,2010,30(1):41-43.
[5] 刘春红,陈文辉,翟琳娜,等.芪连增敏方对糖耐量减退患者胰岛素敏感性和血浆hs-CRP IL-6和TNF-α的干预作用[J].四川中医,2013,31(7):48-50.
[6] 隋艳波,刘莉,谢宁.洋参御糖丸对糖尿病大鼠脂肪组织PI3K信号通路的调控作用[J].中医药学报,2013,41(3):85-87.
[7] 李丽颖,冯悦.2型糖尿病与代谢综合征的临床观察[J].实用糖尿病杂志,2005,1(3):43-49.
[8] 邵发助. 二甲双胍联合中医补肝肾法治疗非酒精性脂肪肝的疗效观察[J].江西医药,2014,49(6):527-529.
[9] 毕宇芳,刘宇.非酒精性脂肪性肝病与2型糖尿病:关系及研究进展[J].内科理论与实践,2011,6(4):265-269.
[10] 吴淑娴,赵梅,廖建红,等.妊娠对小鼠肝脏脂质代谢相关基因表达和核受体的影响[J].中国妇幼保健,2015,30(20):3482-3486.
[11] 杜娆,谢梅林,王恒斌.蛇床子素对小鼠高脂性脂肪肝的治疗作用[J].苏州大学学报(医学版),2011,31(2):221-224.
[12] Neuschwancler-Tetri BA.Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis:the central role of nontriglyceride fatty acid metabolites[J].Hepatology, 2010,52(2):774-788.
[13] 常宝成. 非酒精性脂肪性肝病与2型糖尿病的相关性[J].中国医师进修杂志,2010,33(4):1-3.
[14] 周鑫,韩德五,李素红,等.非酒精性脂肪性肝病在代谢综合征相关的2型糖尿病发病中的作用[J].中国病理生理杂志,2011,7(7):1352-1359.
[15] Abiru S,Migita K,Maedu Y,et al.Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis[J].Liver Int, 2006,26(1):39-45.
[16] Cawthorn WP,Sefhi JK.TNF-α and adipocyte biology[J].FEBS Lett,2008, 582(1):117-131.
[17] Hsieh PS.Inflammatory change of fatty liver induced by intraportal low-dose lipopolysaccharide infusion deteriorates pancreatic insulin in fructose-induced insulin- resistant rats[J].Liver Int,2008,28(8):1167-1175.
[18] 李新,袁莉,李进,等.长期高脂喂养大鼠胰岛素功能变化与胰岛素炎症反应有关[J].中国病理生理杂志,2009,25(5):949-954.
[19] Domanski JP,Park SJ,Harrison SA.Cardiovascular disease and non-alcoholic fatty liver disease:does histologic severity matter?[J].J Clin Gastroenterol,2012,46(5):427-430.
[20] Stepanova M,Rafiq N,Younossi ZM.Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease:a population-based study[J].Gut,2010, 59(10):1410-1415.
[21] Targher G,Bertolini L,Rodella S,et al.Non-alcholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser- treated retinopathy in type 2 diabetic patient[J].Diabetologia,2008,51(3):444-450.
[22] Targher G,Bertolini L,Padovani R,et al.Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients[J].Diabetes Care, 2007,30(5):1212-1218.
[23] Vitola BE,Deivanayagam S,Stein RI,et al.Weight loss reduces liver fat and improves hepatic and skeletal muscle insulin sensitivity in obese adolescents[J].Obesity(Silver Spring),2009, 17(9):1744-1748.
[24] 陆再英. 内科学[M].北京:人民卫生出版社,2008.783-784.
[25] Loomba R,Lutchman G,Kleiner DE,et al.Clinical trial:pilot study of metformin for the treatment of non-alcoholic steatohepatitis[J].Aliment Pharmacol Ther,2009,29(2):172-182.
[26] Aithal GP,Thomas JA,Kaye PV,et al.Randomized,placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis[J].Gastroenterology,2008,135(4): 1176-1184. |
